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Most pathogenic mitochondrial DNA (mtDNA) variants occur in the 22 mtDNA-encoded
tRNA (mt-tRNA) genes. However, despite more than 270 reported mt-tRNA gene mutations,
only 5 reside within mt-tRNAGly (MT-TG).1 We report a rareMT-TG variant and evaluate this,
in addition to all previously reportedMT-TG variants, against the published criteria used to help
determine the pathogenicity of the mt-tRNA variants.2
Case report
A 39 year old woman, born to nonconsanguineous parents, was reviewed in a specialist
mitochondrial disorders clinic. She presented with hearing loss in her late teens followed by
visual impairment, with bilateral cataracts, retinal dystrophy, and subsequent bilateral retinal
detachments in her twenties; hypothyroidism in her thirties; and secondary amenorrhea.
Clinical examination was otherwise normal, apart from short stature. There was no family
history of neuromuscular or neurologic disease. Blood tests, including creatine kinase,
plasma amino acids, acylcarnitine proﬁle, very long chain fatty acids, and white cell enzymes,
were normal. Plasma lactate was elevated (3.70 mmol/L, reference range 0.5–2.2 mmol/L).
Nerve conduction studies and EMG showed no evidence of generalized myopathy or large
ﬁber neuropathy. Histochemical analyses of muscle tissue revealed ragged-red and cyto-
chrome c oxidase (COX) deﬁcient ﬁbers (ﬁgure A). Spectrophotometric determination of
mitochondrial respiratory chain enzyme activities as a ratio to citrate synthase activity3
conﬁrmed decreased activities of complexes I (0.076, reference range 0.104–0.268) and IV
(0.006, reference range 0.014–0.034). Analysis of the next generation sequencing data
(Ilumina MiSeq) of the entire mitochondrial genome extracted from the muscle3 revealed
a rare m.10038G>A variant (GenBank reference accession number: NC_012920.1) in MT-
TG (ﬁgure B) that was present at variable heteroplasmy levels across tissue types: 15%
blood, 40% urinary epithelial cells, and 92% skeletal muscle. Maternal transmission was
conﬁrmed: 3% mutant load was present in the mother’s urinary epithelial cells (method-
ology detects heteroplasmy levels ≥1%). Heteroplasmy levels within individual laser-
captured COX-positive and COX-deﬁcient muscle ﬁbers were quantiﬁed by pyrosequenc-
ing.4 Single ﬁber segregation studies conﬁrmed a higher mutation load in COX-deﬁcient
(mean 95.30% ± 0.50%, SD, n = 27) compared with COX-positive ﬁbers (mean 78.92% ±
4.43%, SD, n = 26; p = 0.0005, ﬁgure C).
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Discussion
The m.10038G nucleotide is highly conserved across species
(ﬁgure D, ﬁgure e-1, links.lww.com/NXG/A248) and the G>A
transition at this location disrupts a C-G Watson-Crick base
pair in the TΨC stem of the tRNA molecule. The
m.10038G>A variant is rare (absent from 3,450 in-house and
48,882 GenBank1 sequences) and detectable at variable het-
eroplasmy levels across diﬀerent tissues, with the highest levels
in the postmitotic muscle. Histochemical and biochemical ev-
idence of reduced complex I and IV activities in the muscle is
supportive of impaired mitochondrial protein synthesis,
whereas single ﬁber studies conﬁrmed segregation of the COX
defect with higher mutant levels. Consequently, the mutation
would be considered “deﬁnitely pathogenic” based on the ac-
cepted criteria for assigning pathogenicity to tRNA mutations
(table e-1, links.lww.com/NXG/A249).2
Review of the 5 previously reportedMT-TG variants according
to these criteria (table e-1, links.lww.com/NXG/A249) reveals
that only 2 variants; m.9997T>C and m.10010T>C, should be
considered “deﬁnitely pathogenic.” Although the m.9997T>C
variant has only been reported in one family, trans-
mitochondrial cybrid studies support its pathogenic eﬀects.
The m.10010T>C variant has been reported a number of
times, and its pathogenicity has been conﬁrmed using single
ﬁber segregation studies. The m.10006A>G variant has only
been reported in individuals harboring additional mtDNA
variants, and thus may represent a benign polymorphism or be
insuﬃcient to cause disease in isolation. Current evidence
suggests that the m.10014A>G variant is a benign poly-
morphism. Finally, although the scoring system indicates that
the m.10044A>G variant is “possibly pathogenic,” it has been
detected in healthy controls, and thus may represent a hap-
logroup speciﬁc polymorphism.5
It remains unclear why pathogenic variants occur more fre-
quently in speciﬁc mt-tRNA genes. Possible explanations in-
clude intensive investigation of mt-tRNAs in which pathogenic
variants have previously been identiﬁed, and survivor bias and
Figure Characterization of a rare pathogenic MT-TG variant
(A) Staining of themuscle sections with haematoxylin and eosin demonstrated ragged-red fibers (*) which were confirmed in the Gomori trichrome preparation
(*)with the inset showing highmagnificationof left top fiber. Anumber of fibers, oftenwith ragged-redmorphology, showedamild increase in thenumber of lipid
droplets with Sudan black (*). Sequential COX and SDH histochemistry demonstrated frequent COX-deficient fibers, some of which had a ragged red–like
appearance (*). The bar represents 100 μm for all stains with the inset 50 μm. (B) Two-dimensional cloverleaf structure of mitochondrial DNA-encoded tRNAGly.
Black arrows indicate previously reported pathogenic variants. Red arrow indicates the rare variant identified in our patient. (C) Single muscle fiber segregation
studies. COX-deficient fibers, (blue circles) harbor a higher mutational load compared with COX-positive fibers (red circles). (D) Evolutionary conservation of the
m.10038G residue across species. COX = cytochrome c oxidase; SDH = succinate dehydrogenase.
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the absence of maternal transmission of mutations in mt-tRNA
genes linked with severe biochemical deﬁciencies, with isolated
cases dissuading clinicians from further investigation of an
underlying mitochondrial disorder.6 Variants in mt-tRNAGly
aﬀecting its canonical or noncanonical functions may also po-
tentially be better tolerated than other mt-tRNAs or, con-
versely, be severely deleterious and embryonic lethal.
The detection of the rare mt-tRNA gene variants in suspected
mitochondrial disease has become more commonplace, given
the widespread availability of whole mtDNA high throughput
sequencing. Furthermore, whole genome sequencing, which
includes capture and deep sequencing of the mitochondrial
genome, is identifying mtDNA variants in those in whom mi-
tochondrial disease may not previously have been considered.
However, despite advances in the DNA sequencing technol-
ogy, the challenge of assigning pathogenicity to the rare
mtDNA variants remains. It is therefore crucial that pathogenic
variants are reported after conﬁrmation using “gold-standard”
techniques, for example, single ﬁber or transmitochondrial
cybrid studies, given the implications to genetic counseling and
the available reproductive options for mtDNA mutations, in-
cluding mitochondrial donation. Moreover, generating a com-
prehensive data set for “deﬁnitely pathogenic” mt-tRNA
variants would potentially advance the understanding of the
molecular mechanisms underpinning the susceptibility of in-
dividual genes to deleterious variants and facilitate the de-
velopment of targeted therapies to treat this group of disorders.
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